Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Would See Added Costs Under U.S. FDA Plan

This article was originally published in PharmAsia News

Executive Summary

A plan under review by the U.S. FDA could have an impact on Japan's Takeda Pharmaceutical and its diabetes drugs worth $2.9 billion in sales. The U.S. agency is considering raising standards that would require existing and new diabetes drugs to have a positive impact on cardiovascular disease and the life span of the patient. That could mean an end to the use of surrogate endpoints currently relied on by drug makers to measure benchmarks. If the FDA moves in that direction, Takeda, GlaxoSmithKline and other makers of diabetes drugs could be required to conduct additional studies to show the improvements. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts